Rhythm data set up submissions for ultra-rare obesity disorders

Two new Phase III readouts pave the way for Rhythm Pharmaceuticals to make its first regulatory submissions for setmelanotide to treat rare genetic disorders that result in obesity.

Rhythm Pharmaceuticals Inc. (NASDAQ:RYTM) said Wednesday that setmelanotide, a small peptide agonist of melanocortin 4 receptor (MC4R), significantly improved the proportion of patients achieving at least 10% change in body weight from baseline to one year, meeting the primary endpoints of Phase III studies to treat obesity associated with pro-opiomelanocortin (POMC) and leptin receptor (LEPR) deficiencies...